Impact Analysis of Covid-19
The complete version of the Report will include the impact of the COVID-19, and anticipated change on the future outlook of the industry, by taking into the account the political, economic, social, and technological parameters.
Chronic diseases often lead to catastrophic damage to vital organs. This damage is usually irreversible and leads to lifetime dependency on medicines. Under such severe conditions, transplants remain the component for restoration of healthy life.
There is increasing demand for tissue and organ transplantation, especially, especially from high income countries. Higher prevalence of diseases such as diabetes, cancer, cardiovascular diseases, renal diseases, and Alzheimer’s disease have posed a threat of irreversible tissue damage to a large population, globally. For instance, according to the Centers for Disease Control and Prevention (CDC) estimations 2019, the chronic kidney disease is more common in people of age 65 years or above and around 125,000 people in the U.S. started treatment for end-stage kidney disease (ESKD) and over 726,000 (2 in every 1,000 people) in 2018 were on dialysis or were living with a kidney transplant.
The global tissue and organ transplantation market is estimated to be valued at US$ 13.9 Billion in 2020 and is expected to exhibit a CAGR of 9.1% during the forecast period (2020-2027).
Figure 1. Global Tissue and Organ Transplantation Market Share (%) Analysis, By Application, 2020
Increasing number of people suffering from organ failure is expected to drive growth of the global tissue and organ transplantation market
According to the World Health Organization (WHO) Global Observatory on Donation and Transplantation 2014, around 119,873 organs are transplanted annually worldwide. Moreover, increasing number of chronic diseases leading to organ failure and habits such as smoking and drinking further leading to organ disability are expected to fuel growth of the tissue and organ transplantation market over the forecast period. For instance, according to the Health Resources and Services Administration, till May 2017, there were around 117,829 patients waiting for organ transplants in the U.S., among which about 97,610 were waiting for kidney transplants. However, only 11,061 transplant procedures were performed from January to April 2017. Thus, increasing number of people awaiting organ and tissue transplant and increasing mortality rate due to the inadequate organ and tissue for transplantation might create opportunities in the tissue and organ transplantation market.
Tissue and Organ Transplantation Market Report Coverage
||Market Size in 2020:
||US$ 13.9 Bn
|Historical Data for:
||2017 to 2019
||2020 to 2027
|Forecast Period 2020 to 2027 CAGR:
||2027 Value Projection:
||US$ 25.6 Bn
- North America: U.S. and Canada
- Latin America: Brazil, Argentina, Mexico, and Rest of Latin America
- Europe: Germany, U.K., Spain, France, Italy, Russia, and Rest of Europe
- Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, and Rest of Asia Pacific
- Middle East: GCC, Israel, and Rest of Middle East
- Africa: South Africa, North Africa, and Central Africa
- By Product Type: Tissue Products, Preservation Solution, Immunosuppressive Drugs.
- By Application: Organ Transplantation, Tissue Transplantation.
- By End User: Hospital, Transplant Centers, Others.
CryoLife, Inc., Folio Biosciences, Arthrex, Abbvie, Inc., Zimmer Biomet, Medtronic PLC, Novartis AG, Stryker Corporation, BiolifeSolutions, Inc. , Teva Pharmaceuticals, and Veloxis Pharmaceutical
- Increasing number of people suffering from organ failure
- Increasing prevalence of chronic diseases
|Restraints & Challenges:
- Shortage of organs for the treatment of organ failure
Tissue and Organ Transplantation Market- Restraints
The shortage of organs for the treatment of organ failure is expected to hamper the global tissue and organ transplantation market growth. There is a huge gap between demand and supply of organs for organ failure treatment. For instance, according to the U.S. Department of Health & Human Services, in 2019, there were around 43,201 patients with kidney transplant requirements in the U.S., however, only 23,401 kidney transplant procedures were performed.
Furthermore, according to the World Health Resources & Services Administration, 17 people die each day waiting for an organ transplant in the U.S.
Tissue and Organ Transplantation Market– Regional Analysis
North America accounted for the largest market share in 2019 in the tissue and organ transplantation market, owing to increasing number of organ transplant surgeries in the U.S. For instance, according to the Mayo Foundation for Medical Education and Research (MFMER), in 2017, around 8,000 liver transplants were performed in the U.S. among both adults and children. Of those, around 360 involved livers from living donors. At the same time, around 11,500 people were registered on the waiting list for a liver transplant.
Furthermore, Asia Pacific is expected to witness the fastest growth during the forecast period, owing to increasing prevalence of chronic diseases. For instance, according to the global burden of disease study 2016, the estimated prevalence of cardiovascular diseases (CVDs) in India was estimated to be 54.5 million. One in 4 deaths in India is due to CVDs including ischemic heart disease and stroke.
Figure 2. Global Tissue and Organ Transplantation Market Value (US$ Mn) & Y-o-Y Growth (%), 2017-2027
Tissue and Organ Transplantation Market- Competitive Landscape
Key players operating in the tissue and organ transplantation market include CryoLife, Inc., Folio Biosciences, Arthrex, Abbvie, Inc., Zimmer Biomet, Medtronic PLC, Novartis AG, Stryker Corporation, BiolifeSolutions, Inc. , Teva Pharmaceuticals, and Veloxis Pharmaceutical.